Generic ARGININE HYDROCHLORIDE INN entry, drug patent expiry and freedom to operate

Sponsor	Phase
AstraZeneca	PHASE2
Joshua Palmer	PHASE1
RayzeBio, Inc.	PHASE1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	R-GENE 10	arginine hydrochloride	INJECTABLE;INJECTION	016931-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Arginine hydrochloride is a synthetic amino acid salt with established therapeutic applications and potential for new indications. Its patent landscape reveals a mature market with a focus on formulation improvements, new delivery methods, and combination therapies. The financial trajectory is influenced by generic competition, the development of novel analogs, and market demand for its existing uses, primarily in treating hyperammonemia and as a vasodilator.

What are the key therapeutic areas for arginine hydrochloride?

Arginine hydrochloride's primary therapeutic application is in the management of hyperammonemia, a condition characterized by excessive levels of ammonia in the blood. Ammonia is a byproduct of protein metabolism, and its accumulation can lead to severe neurological damage. Arginine plays a crucial role in the urea cycle, a metabolic pathway that converts ammonia into urea, which can then be excreted from the body. Arginine hydrochloride is administered to supplement the body's urea cycle and promote ammonia detoxification.

Beyond hyperammonemia, arginine hydrochloride has been explored and utilized for its vasodilatory properties. L-arginine, the precursor to nitric oxide (NO), a potent vasodilator, is involved in the synthesis of NO. Vasodilation can improve blood flow and has implications for various cardiovascular conditions, though its use in this context is often secondary or investigational.

Specific areas of application include:

Inborn errors of urea cycle disorders: This is the most significant application. Conditions such as ornithine transcarbamylase deficiency and carbamoyl phosphate synthetase I deficiency result in severe hyperammonemia, for which arginine hydrochloride is a cornerstone treatment.
Acute liver failure: In cases of acute liver failure, the liver's capacity to process ammonia is compromised, leading to hyperammonemia. Arginine hydrochloride can be used as an adjunctive therapy.
Post-operative recovery: Some studies suggest potential benefits in promoting wound healing and reducing sepsis risk in surgical patients, attributed to arginine's role in protein synthesis and immune function.
Cardiovascular health: While not a primary indication, its vasodilatory potential has led to its investigation in conditions like erectile dysfunction and peripheral artery disease, though evidence for widespread clinical adoption in these areas is less robust than for hyperammonemia.

The drug is typically administered intravenously, allowing for rapid delivery and effective management of acute hyperammonemic crises. Oral formulations are also available for chronic management of urea cycle disorders.

What is the current patent landscape for arginine hydrochloride?

The patent landscape for arginine hydrochloride is characterized by a foundational period of composition of matter patents that have long since expired. Current patent activity focuses on secondary inventions related to its use and formulation. This indicates a mature market where innovation is centered on improving existing therapies rather than discovering entirely new molecular entities.

Key areas of patenting activity include:

Novel formulations and delivery systems: Patents often cover enhanced stability, improved bioavailability, or modified release profiles for both intravenous and oral administration. This can include lyophilized formulations for longer shelf life or specific intravenous infusion protocols designed to optimize therapeutic effect and minimize side effects.
Combination therapies: Research and patent filings explore the synergistic effects of arginine hydrochloride when combined with other therapeutic agents. This is particularly relevant in managing complex conditions where multiple pathways require intervention. For instance, combinations might target ammonia reduction and support for liver function simultaneously.
Specific medical indications and treatment protocols: While the general use for hyperammonemia is well-established, new patents may claim specific dosing regimens, treatment durations, or patient populations for improved outcomes. This includes patents related to the management of hyperammonemia in specific neonatal conditions or during particular phases of illness.
Manufacturing processes: Patents may also cover more efficient or cost-effective methods for synthesizing arginine hydrochloride, though these are less common for widely established generic compounds.

Major pharmaceutical companies and smaller biotech firms are active in this space, often seeking to differentiate their products through proprietary formulation technologies or unique therapeutic applications. The absence of broad composition of matter patents means that generic manufacturers face fewer barriers to entry for the basic compound, driving competition. Innovation is therefore crucial for companies aiming to maintain market exclusivity or command premium pricing.

Who are the key players and what are their market shares?

The market for arginine hydrochloride is bifurcated. The basic compound is largely dominated by generic manufacturers, while specialty formulations or specific indication approvals may see a more concentrated group of players. Due to the nature of the compound and its long history of use, definitive, publicly disclosed market share data for specific arginine hydrochloride products is not readily available. However, market dynamics can be inferred from the types of companies involved and the product portfolios they offer.

Generic Manufacturers: A significant portion of the arginine hydrochloride market comprises generic versions, primarily for intravenous administration in hospital settings. Companies specializing in generic injectables are key players here. These include:

Hospira (now part of Pfizer): Historically a major supplier of generic injectables.
Fresenius Kabi: A global leader in infusion therapy and clinical nutrition, with a broad portfolio of generic intravenous drugs.
Baxter International: Another significant player in generic injectables and hospital pharmaceuticals.
Numerous other regional and global generic pharmaceutical companies.

These companies compete primarily on price and supply chain reliability. Their market share is largely determined by their manufacturing capacity, distribution networks, and ability to secure contracts with healthcare providers.

Specialty and Branded Players: These players focus on proprietary formulations, combination therapies, or specific, often niche, indications. Their market share, though potentially smaller in overall volume compared to generics, can command higher revenue due to product differentiation and patent protection.

BioMarin Pharmaceutical Inc.: While not exclusively focused on arginine hydrochloride, BioMarin is a leader in rare genetic diseases, including urea cycle disorders. They may offer branded treatments or combination therapies that incorporate or compete with arginine hydrochloride, aiming for improved patient outcomes in these specific populations. Their focus is on disease-specific, often highly regulated, markets.
Orphan drug developers: Companies focusing on orphan indications may develop specialized arginine hydrochloride formulations or combination products for rare urea cycle disorders.

It is important to note that many of these specialty players might not directly market a standalone "arginine hydrochloride" product but rather integrate its therapeutic benefits within a broader treatment regimen for specific genetic or metabolic disorders.

The market share is thus distributed across a broad base of generic suppliers for standard formulations and a more focused group of specialty companies for differentiated or indication-specific offerings. The primary driver for revenue growth in the generic segment is volume, while in the specialty segment, it is innovation and the ability to address unmet medical needs.

What are the financial projections and revenue drivers for arginine hydrochloride?

The financial projections for arginine hydrochloride are influenced by several factors, primarily the balance between generic erosion and the potential for new applications or improved formulations. The market is considered mature for its primary indication of hyperammonemia, leading to stable but not explosive growth in that segment.

Revenue Drivers:

Demand for Hyperammonemia Treatment: The persistent prevalence of urea cycle disorders and acute liver failure globally ensures a baseline demand for arginine hydrochloride. This is the most stable and significant revenue driver.
Generic Competition: The presence of numerous generic manufacturers exerts downward pressure on pricing for standard intravenous formulations. This limits revenue growth for basic arginine hydrochloride products, forcing generic players to compete on volume and efficiency.
Specialty Formulations and Delivery Systems: Patents protecting novel formulations (e.g., extended-release oral, improved stability IV) can allow manufacturers to command premium pricing and extend market exclusivity. These innovations can drive revenue by offering distinct advantages over generic alternatives.
Investigational and New Indications: While current revenue is largely tied to hyperammonemia, successful clinical trials and subsequent approvals for new indications (e.g., specific cardiovascular conditions, sepsis management, wound healing) could significantly boost revenue. However, the bar for demonstrating efficacy and safety in new areas is high.
Geographic Market Expansion: Increased access to healthcare and diagnostic capabilities in emerging markets can lead to higher diagnosis rates for urea cycle disorders, thereby increasing demand for treatment.
Combination Therapies: Development and approval of combination products where arginine hydrochloride is a key component can create new revenue streams, especially if they offer superior efficacy or convenience for complex conditions.

Financial Projections:

Mature Market Growth: The overall market for arginine hydrochloride, considering its primary use, is projected to experience low single-digit annual growth (1-3%). This reflects the stable demand from hyperammonemia treatment offset by price competition.
Segmented Performance:
- Generic Injectables: Revenue growth in this segment will be largely volume-driven, with pricing remaining competitive. Profitability will depend on manufacturing costs and supply chain efficiency.
- Specialty/Branded Products: Products with patent protection for novel formulations or specific indications are expected to show higher growth rates, potentially in the mid-to-high single digits (5-10%), due to premium pricing and limited competition.
R&D Investment Impact: Significant R&D investment in new indications or formulations could lead to more substantial growth in specific sub-segments, but this is highly dependent on clinical trial success and regulatory approval.
Competition from Analogs: The development of alternative therapies or direct competitors to arginine in managing hyperammonemia or promoting vasodilation could impact future revenue.

Overall, the financial trajectory is one of steady demand, moderated by generic pricing pressures, with opportunities for growth tied to innovation in formulation, delivery, and the successful pursuit of new therapeutic applications.

What are the regulatory considerations and manufacturing challenges?

The regulatory and manufacturing landscape for arginine hydrochloride is influenced by its status as both a well-established pharmaceutical ingredient and a substance with potential for new therapeutic claims.

Regulatory Considerations:

Existing Approvals: Arginine hydrochloride has established regulatory approvals for its primary indication (hyperammonemia) by major regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals are based on extensive clinical data regarding safety and efficacy for these specific uses.
Generic Drug Approval Pathways: For generic versions, manufacturers must demonstrate bioequivalence to the reference listed drug. This involves Abbreviated New Drug Applications (ANDAs) in the U.S. or similar processes in other regions, focusing on equivalence in dosage form, strength, route of administration, quality, performance characteristics, and intended use.
New Indication Approval: Seeking approval for new therapeutic uses beyond hyperammonemia requires comprehensive clinical trials to establish safety and efficacy for the novel indication. This is a lengthy and expensive process, requiring Phase I, II, and III studies. The burden of proof for new indications is substantial.
Orphan Drug Designation: For rare diseases, including specific urea cycle disorders, obtaining Orphan Drug Designation can provide market exclusivity for a period, potentially incentivizing development of specialized arginine hydrochloride formulations or therapies.
Good Manufacturing Practices (GMP): All manufacturers must adhere to strict GMP guidelines established by regulatory authorities. This ensures product quality, purity, and consistency. Compliance involves rigorous quality control, validated manufacturing processes, and robust documentation.
Pharmacopeial Standards: Arginine hydrochloride must meet the standards set by official pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.), which define identity, strength, quality, and purity specifications.

Manufacturing Challenges:

Sourcing and Purity of Raw Materials: Ensuring a consistent supply of high-purity L-arginine and hydrochloric acid is critical. Impurities in raw materials can affect the final product's quality and safety. Supply chain integrity and rigorous vendor qualification are essential.
Sterility and Pyrogenicity (for Injectables): Manufacturing injectable arginine hydrochloride requires aseptic processing techniques to ensure sterility and the absence of pyrogens (fever-inducing substances). This demands specialized facilities, stringent environmental controls, and validated sterilization processes.
Formulation Stability: Developing stable liquid or lyophilized formulations, especially for intravenous use, can be challenging. Factors like pH, temperature, light exposure, and excipient compatibility must be carefully controlled to prevent degradation and maintain potency over the product's shelf life.
Scale-Up: Transitioning from laboratory-scale synthesis and formulation to large-scale commercial manufacturing requires significant process optimization and validation to maintain consistent product quality and yield.
Cost Management: For generic manufacturers, efficient and cost-effective manufacturing processes are paramount to remain competitive in a price-sensitive market. This involves optimizing yields, minimizing waste, and leveraging economies of scale.
Complex Formulations: Developing advanced formulations, such as sustained-release oral dosage forms or novel delivery systems, introduces additional manufacturing complexities related to particle size control, coating technologies, or encapsulation methods.

The interplay of stringent regulatory requirements and the technical challenges of pharmaceutical manufacturing shapes the production and market access for arginine hydrochloride.

Key Takeaways

Arginine hydrochloride's market is mature for its primary hyperammonemia indication, characterized by significant generic competition and limited pricing power for standard formulations. Patent activity is focused on formulation enhancements, novel delivery systems, and combination therapies, aiming to create value beyond the basic compound. Financial projections indicate low single-digit growth for the overall market, with specialty formulations and new indications offering potential for higher returns. Regulatory considerations center on existing approvals for hyperammonemia, generic bioequivalence, and the rigorous demands of new indication development. Manufacturing challenges include ensuring raw material purity, maintaining sterility for injectables, and achieving formulation stability.

FAQs

What is the primary economic driver for arginine hydrochloride sales? The primary economic driver is the ongoing demand for treating hyperammonemia, particularly in patients with urea cycle disorders and acute liver failure.
How do patents influence the pricing of arginine hydrochloride? Patents on novel formulations, delivery methods, or specific medical indications can allow manufacturers to charge premium prices and maintain market exclusivity for a limited time, differentiating them from generic competition.
Are there significant R&D investments in entirely new applications for arginine hydrochloride? While some investigational research explores new applications, the bulk of R&D is focused on improving existing formulations and delivery methods for established uses, rather than developing entirely new therapeutic categories.
What distinguishes the market for generic arginine hydrochloride from specialty formulations? The generic market is driven by volume and price competition, serving broad hyperammonemia treatment needs. Specialty formulations target specific patient groups or offer enhanced product attributes, commanding higher prices and aiming for niche market share.
What are the main challenges in manufacturing arginine hydrochloride for intravenous use? Key challenges include ensuring absolute sterility, preventing pyrogen contamination, and maintaining long-term formulation stability under various storage and handling conditions.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases [2] European Medicines Agency. (n.d.). Medicines. Retrieved from https://www.ema.europa.eu/en/medicines [3] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf [4] European Pharmacopoeia. (n.d.). Ph. Eur. Home. Retrieved from https://www.edqm.eu/en/ph-eur-home [5] BioMarin Pharmaceutical Inc. (n.d.). Our Therapies. Retrieved from https://www.biomarin.com/our-therapies/ [6] Fresenius Kabi. (n.d.). Products. Retrieved from https://www.fresenius-kabi.com/global/products

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	145
Clinical Trials:	419
What excipients (inactive ingredients) are in arginine hydrochloride?	arginine hydrochloride excipients list
DailyMed Link:	arginine hydrochloride at DailyMed

Arginine hydrochloride - Generic Drug Details

What are the generic drug sources for arginine hydrochloride and what is the scope of freedom to operate?

Summary for arginine hydrochloride

Recent Clinical Trials for arginine hydrochloride

Anatomical Therapeutic Chemical (ATC) Classes for arginine hydrochloride

US Patents and Regulatory Information for arginine hydrochloride

Arginine Hydrochloride: Patent Landscape and Market Dynamics